State-of-the-Art in Neuropathology

A special issue of Journal of Molecular Pathology (ISSN 2673-5261).

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 1693

Special Issue Editors


E-Mail Website
Guest Editor
Programme Lead MClinDent and MSc in Clinical Periodontology, Senior Lecturer in Periodontology, Honorary Consultant UHMBT (Lancaster), Faculty of Clinical and Biomedical Sciences, School of Medicine and Dentistry, University of Central Lancashire, Harrington Building, Preston PR1 2HE, UK
Interests: periodontitis; microbiology; neurodegeneration

E-Mail Website
Guest Editor
Neurology and Neurorehabilitation Unit, I.R.C.C.S. “Santa Lucia” Foundation, Via Ardeatina 306, 00179 Rome, Italy
Interests: neuropsychology; neurodegeneration; self-rated disability; clinical assessment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Neuropathology is a discipline that nowadays encompasses many fields of medicine as the primary effect of neurological diseases or as the secondary effect of a systemic involvement from other conditions. Neuroinflammation in general as part of a chronic inflammatory state leads to a progressive cognitive decline and dementia or to different neural dysfunctions. The actual knowledge and the availability of lab and clinical advanced investigations have shed some light regarding the cellular involvement and its components, as mitochondria, the cytoskeleton and the membrane; however, further research is needed to combine the ultrastructural damage with the clinical signs and symptoms.  

This Special Issue of the Journal of Molecular Pathology focuses on the recent advances in neurodegeneration to provide new evidence regarding the correlation between molecular and structural cell damage and the clinical semeiology with a particular focus on neuroinflammatory diseases leading to cognitive impairment and dementia.

You are welcome to submit new research papers and reviews to this Special Issue. Other acceptable manuscript types include methodological papers, position papers, brief reports, and commentaries.

We look forward to receiving your contributions.

Dr. Flavio Pisani
Dr. Valerio Pisani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Molecular Pathology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neuropathology
  • neuroinflammation
  • cognitive impairment
  • dementia

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

12 pages, 2692 KiB  
Systematic Review
IL10 Gene and Neurodegenerative Sclerosis: A Systematic Review and Meta-Analysis
by Ismael Duarte Machado de Almeida, Pedro Luiz de Paiva, Kamilla de Faria Santos, Angela Adamski da Silva Reis and Rodrigo da Silva Santos
J. Mol. Pathol. 2023, 4(4), 213-224; https://doi.org/10.3390/jmp4040019 - 29 Sep 2023
Viewed by 1193
Abstract
Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) are incurable degenerative scleroses with unclear etiology. Neuroinflammation is an important factor in the neurodegeneration characteristic of these diseases. Additionally, Interleukin 10 (IL10) can inhibit the synthesis of inflammatory cytokines and plays a protective role [...] Read more.
Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) are incurable degenerative scleroses with unclear etiology. Neuroinflammation is an important factor in the neurodegeneration characteristic of these diseases. Additionally, Interleukin 10 (IL10) can inhibit the synthesis of inflammatory cytokines and plays a protective role against neurodegeneration associated with neuroinflammation. Thus, we developed a systematic review and meta-analysis in order to clarify the relationship between polymorphisms in the IL10 gene and MS and/or ALS. We searched for observational studies in four international databases without time restrictions. Seventeen studies were added to the systematic review and six polymorphisms were observed: IL10-592 (rs1800872; C>A), IL10-819 (rs1800871; C>T), IL10-1082 (rs1800896; A>G), IL10-2763 (rs6693899; A>C), IL10-2849 (rs6703630; A>G) and IL10-3575 (rs1800890; A>T). In the meta-analysis, we used odds ratio (OR) and 95% confidence interval (CI) to evaluate the association of IL10-1082, IL10-819 and IL10-592 polymorphisms and MS. We found a positive association of MS with the IL10-1082 SNP in genotypic comparison (AG+GG vs. AA) (OR = 1.23; 95% CI = 1.01–1.51; p = 0.04). Our search did not find any article relating polymorphisms in the IL10 gene with ALS. Therefore, our analysis indicates a possible association of IL10 gene SNPs in the development and progression of MS. Full article
(This article belongs to the Special Issue State-of-the-Art in Neuropathology)
Show Figures

Figure 1

Back to TopTop